REG - Genflow Biosciences - Notice of AGM

Genflow BiosciencesAnnouncement

03/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240603:nRSC7241Qa&default-theme=true

RNS Number : 7241Q  Genflow Biosciences PLC  03 June 2024

 

3 June 2024

Genflow Biosciences Plc

Notice of Annual General Meeting

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company")
an emerging leader in the field of longevity research, focused on developing
therapeutic solutions for the prevention of age-related diseases is pleased to
announce that it will hold its Annual General Meeting ("AGM") at 12pm on
Thursday 27 June 2024 at 1 Heddon Street, London, W1B 4BT.

The Notice of the AGM ("Notice") and 2024 Form of Proxy will shortly be
available on the Company's website, www.genflowbio.com
(http://www.genflowbio.com) , and have, where applicable, been posted to
shareholders. Further details of the arrangements for this year's AGM are set
out in the Notice.

As announced on 7 May 2024, the Company's Annual Report and Accounts for the
year ended 31 December 2023 are also available on the website and has, where
applicable, also been posted to registered shareholders.

Contacts

 Genflow Biosciences            Harbor Access
 Dr Eric Leire, CEO             Jonathan Paterson, Investor Relations
 +32-477-495-881                +1 475 477 9401
                                Jonathan.Paterson@Harbor-access.com

 Joint Corporate Brokers

 Clear Capital Markets          Capital Plus Partners Ltd
 Bob Roberts, +44 203 869 6080  Dominic Berger, +44 203 821 6167
                                Keith Swann, +44 0203 821 6169
                                Jon Critchley, +44 0203 821 6168

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn and Twitter/X.

 

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAQKDBPPBKDCPN